HUP0001122A3 - Farnesyltransferase inhibiting quinazolinones - Google Patents
Farnesyltransferase inhibiting quinazolinonesInfo
- Publication number
- HUP0001122A3 HUP0001122A3 HU0001122A HUP0001122A HUP0001122A3 HU P0001122 A3 HUP0001122 A3 HU P0001122A3 HU 0001122 A HU0001122 A HU 0001122A HU P0001122 A HUP0001122 A HU P0001122A HU P0001122 A3 HUP0001122 A3 HU P0001122A3
- Authority
- HU
- Hungary
- Prior art keywords
- quinazolinones
- farnesyltransferase inhibiting
- farnesyltransferase
- inhibiting
- inhibiting quinazolinones
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 title 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97201259 | 1997-04-25 | ||
PCT/EP1998/002357 WO1998049157A1 (en) | 1997-04-25 | 1998-04-17 | Farnesyltransferase inhibiting quinazolinones |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0001122A2 HUP0001122A2 (hu) | 2001-04-28 |
HUP0001122A3 true HUP0001122A3 (en) | 2002-03-28 |
Family
ID=8228267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0001122A HUP0001122A3 (en) | 1997-04-25 | 1998-04-17 | Farnesyltransferase inhibiting quinazolinones |
Country Status (22)
Country | Link |
---|---|
US (2) | US6177432B1 (hu) |
EP (1) | EP0977750B1 (hu) |
JP (1) | JP4308919B2 (hu) |
KR (1) | KR100520401B1 (hu) |
CN (1) | CN1094937C (hu) |
AT (1) | ATE366250T1 (hu) |
AU (1) | AU738628B2 (hu) |
BR (1) | BR9809398A (hu) |
CA (1) | CA2288140C (hu) |
CZ (1) | CZ296959B6 (hu) |
DE (1) | DE69838025T2 (hu) |
ES (1) | ES2289783T3 (hu) |
HU (1) | HUP0001122A3 (hu) |
IL (1) | IL130363A (hu) |
NO (1) | NO317576B1 (hu) |
NZ (1) | NZ336233A (hu) |
PL (1) | PL190944B1 (hu) |
RU (1) | RU2205831C2 (hu) |
SK (1) | SK146199A3 (hu) |
TR (1) | TR199902606T2 (hu) |
WO (1) | WO1998049157A1 (hu) |
ZA (1) | ZA983504B (hu) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100520401B1 (ko) * | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
EA003510B1 (ru) | 1998-07-06 | 2003-06-26 | Янссен Фармацевтика Н.В. | Ингибиторы фарнезилпротеинтрансферазы, применяемые для лечения артропатий |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6284755B1 (en) | 1998-12-08 | 2001-09-04 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
SI1140935T1 (en) | 1998-12-23 | 2003-10-31 | Janssen Pharmaceutica N.V. | 1,2-annelated quinoline derivatives |
KR20010077400A (ko) * | 2000-02-02 | 2001-08-17 | 성재갑 | 에프타아제 저해제인 엘비42908과 타(他) 항암제와의조합에 의한 항암치료제 |
DE60118889T2 (de) * | 2000-02-04 | 2006-11-30 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs |
CA2397558A1 (en) | 2000-02-24 | 2001-08-30 | Janssen Pharmaceutica N.V. | Dosing regimen |
JP2003525252A (ja) * | 2000-02-29 | 2003-08-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Her2抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 |
US20030181473A1 (en) * | 2000-02-29 | 2003-09-25 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with taxane compounds |
AU2001244166A1 (en) * | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
CA2397475A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
WO2001064197A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
EP1261342A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations |
US20030078281A1 (en) * | 2000-02-29 | 2003-04-24 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents |
EP1261343A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
WO2001064194A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
DE60118225T2 (de) * | 2000-09-25 | 2007-05-03 | Janssen Pharmaceutica N.V. | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren |
JP4974437B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−[(置換フェニル)メチル]−キノリンおよびキナゾリン誘導体 |
EP1322650B1 (en) * | 2000-09-25 | 2008-09-24 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
JP4974439B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体 |
DE60139080D1 (de) | 2000-11-21 | 2009-08-06 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
ATE323490T1 (de) * | 2000-11-28 | 2006-05-15 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung |
EP1347966B1 (en) * | 2000-12-27 | 2006-03-08 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
DE60230017D1 (de) * | 2001-02-15 | 2009-01-08 | Janssen Pharmaceutica Nv | Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen |
PL208238B1 (pl) | 2001-03-12 | 2011-04-29 | Janssen Pharmaceutica Nv | Sposób wytwarzania 4- (3-chlorofenylo) -6- [ (4-chlorofenylo) hydroksy (1-metylo-1H-imidazol-5-ilo) metylo] -1-metylo-2 (1H) -chinolinonu |
US20020177575A1 (en) * | 2001-05-04 | 2002-11-28 | Ward Wakeland | Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies |
DE60231646D1 (de) * | 2001-12-19 | 2009-04-30 | Janssen Pharmaceutica Nv | Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren |
FR2837201A1 (fr) * | 2002-03-18 | 2003-09-19 | Servier Lab | Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US7241777B2 (en) | 2002-03-22 | 2007-07-10 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
AU2003229688B2 (en) | 2002-04-15 | 2009-07-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
US20030125268A1 (en) * | 2002-08-28 | 2003-07-03 | Rybak Mary Ellen Margaret | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
WO2005089496A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
EP1655289A1 (en) * | 2004-11-04 | 2006-05-10 | Embl | Quinazoline derivatives, process for their preparation, their use as antimitotics and pharmaceutical compositions comprising said derivatives |
PL2362218T3 (pl) | 2004-11-05 | 2015-02-27 | Janssen Pharmaceutica Nv | Sposoby kontroli skuteczności inhibitorów transferazy farnezylowej |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
KR101356748B1 (ko) | 2005-04-19 | 2014-02-06 | 스미스클라인 비이참 (코르크) 리미티드 | 약제 조성물 |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
EP1968591A4 (en) | 2005-12-23 | 2010-02-17 | Link Medicine Corp | TREATMENT OF SYNUCLEINOPATHIES |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
EP2021335B1 (en) | 2006-04-20 | 2011-05-25 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
UA93085C2 (en) | 2006-04-20 | 2011-01-10 | Янссен Фармацевтика Н.В. | Inhibitors of c-fms kinase |
JP5256202B2 (ja) | 2006-09-11 | 2013-08-07 | エム・エス・ディー・オス・ベー・フェー | キナゾリノンおよびイソキノリノンアセトアミド誘導体 |
JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2370436A1 (en) * | 2008-11-13 | 2011-10-05 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
HRP20171415T4 (hr) * | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
JP6034784B2 (ja) | 2010-07-28 | 2016-11-30 | ジャンセン ダイアグノスティックス,エルエルシー | ファルネシルトランスフェラーゼ阻害剤による治療に対する急性白血病応答を判定するための方法 |
JP6359537B2 (ja) | 2012-08-07 | 2018-07-18 | ヤンセン ファーマシューティカ エヌ.ベー. | 複素環エステル誘導体の調製プロセス |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
CN103275085B (zh) * | 2013-05-30 | 2015-04-08 | 温州大学 | 一种喹唑啉并喹唑啉酮化合物及其合成方法和用途 |
EP3385395B9 (en) * | 2015-08-17 | 2020-05-20 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyl transferase inhibitors |
WO2018085518A2 (en) | 2016-11-03 | 2018-05-11 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
WO2019113269A1 (en) | 2017-12-08 | 2019-06-13 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
US20220143006A1 (en) | 2019-03-15 | 2022-05-12 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2002864C (en) * | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
US5646154A (en) * | 1992-10-07 | 1997-07-08 | Sumitomo Pharmaceuticals Co., Ltd. | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
TW321649B (hu) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
KR100520401B1 (ko) * | 1997-04-25 | 2005-10-12 | 얀센 파마슈티카 엔.브이. | 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논 |
-
1998
- 1998-04-17 KR KR10-1999-7005507A patent/KR100520401B1/ko not_active IP Right Cessation
- 1998-04-17 CA CA002288140A patent/CA2288140C/en not_active Expired - Lifetime
- 1998-04-17 US US09/403,705 patent/US6177432B1/en not_active Expired - Lifetime
- 1998-04-17 CN CN98804366A patent/CN1094937C/zh not_active Expired - Lifetime
- 1998-04-17 AT AT98924161T patent/ATE366250T1/de not_active IP Right Cessation
- 1998-04-17 NZ NZ336233A patent/NZ336233A/xx unknown
- 1998-04-17 WO PCT/EP1998/002357 patent/WO1998049157A1/en active IP Right Grant
- 1998-04-17 RU RU99124815/04A patent/RU2205831C2/ru active
- 1998-04-17 TR TR1999/02606T patent/TR199902606T2/xx unknown
- 1998-04-17 IL IL13036398A patent/IL130363A/en not_active IP Right Cessation
- 1998-04-17 AU AU76460/98A patent/AU738628B2/en not_active Expired
- 1998-04-17 EP EP98924161A patent/EP0977750B1/en not_active Expired - Lifetime
- 1998-04-17 HU HU0001122A patent/HUP0001122A3/hu unknown
- 1998-04-17 BR BR9809398-3A patent/BR9809398A/pt not_active Application Discontinuation
- 1998-04-17 PL PL336468A patent/PL190944B1/pl unknown
- 1998-04-17 DE DE69838025T patent/DE69838025T2/de not_active Expired - Lifetime
- 1998-04-17 JP JP54656198A patent/JP4308919B2/ja not_active Expired - Lifetime
- 1998-04-17 ES ES98924161T patent/ES2289783T3/es not_active Expired - Lifetime
- 1998-04-17 CZ CZ0371799A patent/CZ296959B6/cs not_active IP Right Cessation
- 1998-04-17 SK SK1461-99A patent/SK146199A3/sk unknown
- 1998-04-24 ZA ZA9803504A patent/ZA983504B/xx unknown
-
1999
- 1999-10-22 NO NO19995169A patent/NO317576B1/no unknown
-
2000
- 2000-10-13 US US09/687,153 patent/US6358961B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0001122A3 (en) | Farnesyltransferase inhibiting quinazolinones | |
PL343481A1 (en) | Dihydropyrimidines | |
GB2346937B (en) | Sprayhead | |
GB9812853D0 (en) | Showerhead | |
AU136016S (en) | Dish | |
GB9704776D0 (en) | Detergent - packaging combination | |
GB9709717D0 (en) | Case | |
ZA985326B (en) | Aminospiropiperidine quinazoline derivatives | |
GB2323866B (en) | Gutters | |
GB9918273D0 (en) | Manfacturing assembly | |
GB9706826D0 (en) | Gutters | |
HU9700115V0 (en) | Case | |
TW415458U (en) | Fixed-type smoke-collection panel | |
AU132841S (en) | Guttering | |
AU137541S (en) | Fascia | |
GB9711221D0 (en) | Malaria treatment | |
AU133555S (en) | Numeral case | |
PL106251U1 (en) | Wash-basin | |
GB9717852D0 (en) | Effective insurance | |
HU9700114V0 (en) | Case | |
GB9717801D0 (en) | Polymerase | |
IL150715A0 (en) | Substituted pyrimidines | |
GB9703906D0 (en) | Locking arrangements | |
IL166937A (en) | Uracil compounds | |
AU131720S (en) | Deadlock case |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |